IOVA - +80% upside with RR 1:5Set-up perfectly for a continuation and a retest of $18.
Breakout due.
Momentum building.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.50 USD
−444.04 M USD
1.19 M USD
247.12 M
About Iovance Biotherapeutics, Inc.
Sector
Industry
CEO
Frederick G. Vogt
Website
Headquarters
San Carlos
Founded
2007
FIGI
BBG000FTLBV7
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
IOVA A look at IOVA daily Fib channel levels. Lookin at historical (split adjusted) and current trading levels. Bold channel is current, secondary channel split adjusted. 8.33 key support. Trade above 9.50 very bullish, to $14 liquidity check and higher if breaks out of liquidity box.
IOVA going to hit $28... could be?The stock broke a resistance level yesterday with huge volume
Buy - $12 (yesterday)
Target - $28
Not a recommendation of course
There are always opportunities... you just have to know where to find them (-:
NASDAQ:IOVA
IOVA a volatile medical stock approaches earnings LONGIOVA has doubled in February and broke out above its volume profile high volume area about
one week ago as it runs to earnings. Since it settled down two days ago into a relative side-
ways consolidation. I will take a long trade here for a pre-earnings play to presume that the
buying and bull
FDA Grants Approval to Iovance's AMTAGVI for Advanced Melanoma
In a significant stride towards revolutionizing cancer treatment, Iovance Biotherapeutics, Inc. (NASDAQ: NASDAQ:IOVA ) has achieved a monumental milestone. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Iovance's AMTAGVI™ (lifileucel) suspension for intravenous infu
IOVA Iovance Biotherapeutics Options Ahead of EarningsAnalyzing the options chain of IOVA Iovance Biotherapeutics prior to the earnings report this week,
I would consider purchasing the 7.5usd strike price Puts with
an expiration date of 2023-6-16,
for a premium of approximately $0.70
If these options prove to be profitable prior to the earnings releas
IOVA - upcoming catalystThis is not a financial advice!
I see first a pullback coming, w8 for it and watch PA closely before entering.
Most info on the chart.
Trade carefully!
IOVA Rising Wedge BreakdownIOVA formed a large bearish Rising Wedge on this Weekly timeframe
This has led to a big downward move, which correlates well with the rising wedge, being a primarily bearish pattern
Support has yet to be found on the Weekly timeframe
Iovance BioTherapeutics (NASDAQ: $IOVA) Popping Pre-market! 🎉Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead pro
Iovance Biotherapeutics bearishIovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte therapies against cancer.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IOVA is 10.59 USD — it has decreased by −13.80% in the past 24 hours. Watch Iovance Biotherapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Iovance Biotherapeutics, Inc. stocks are traded under the ticker IOVA.
IOVA stock has fallen by −0.33% compared to the previous week, the month change is a 9.80% rise, over the last year Iovance Biotherapeutics, Inc. has showed a 146.16% increase.
We've gathered analysts' opinions on Iovance Biotherapeutics, Inc. future price: according to them, IOVA price has a max estimate of 34.00 USD and a min estimate of 10.00 USD. Watch IOVA chart and read a more detailed Iovance Biotherapeutics, Inc. stock forecast: see what analysts think of Iovance Biotherapeutics, Inc. and suggest that you do with its stocks.
IOVA reached its all-time high on Jun 7, 2011 with the price of 165.00 USD, and its all-time low was 1.01 USD and was reached on May 3, 2013. View more price dynamics on IOVA chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
IOVA stock is 31.90% volatile and has beta coefficient of 2.34. Track Iovance Biotherapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Iovance Biotherapeutics, Inc. there?
Today Iovance Biotherapeutics, Inc. has the market capitalization of 3.23 B, it has increased by 4.55% over the last week.
Yes, you can track Iovance Biotherapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Iovance Biotherapeutics, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
IOVA earnings for the last quarter are −0.28 USD per share, whereas the estimation was −0.30 USD resulting in a 6.31% surprise. The estimated earnings for the next quarter are −0.26 USD per share. See more details about Iovance Biotherapeutics, Inc. earnings.
Iovance Biotherapeutics, Inc. revenue for the last quarter amounts to 58.55 M USD, despite the estimated figure of 53.79 M USD. In the next quarter, revenue is expected to reach 72.36 M USD.
IOVA net income for the last quarter is −83.54 M USD, while the quarter before that showed −97.10 M USD of net income which accounts for 13.96% change. Track more Iovance Biotherapeutics, Inc. financial stats to get the full picture.
No, IOVA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 9, 2024, the company has 557.00 employees. See our rating of the largest employees — is Iovance Biotherapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Iovance Biotherapeutics, Inc. EBITDA is −388.32 M USD, and current EBITDA margin is −35.95 K%. See more stats in Iovance Biotherapeutics, Inc. financial statements.
Like other stocks, IOVA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Iovance Biotherapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Iovance Biotherapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Iovance Biotherapeutics, Inc. stock shows the buy signal. See more of Iovance Biotherapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.